Taysha Gene Therapies Sees Unusually High Options Volume (NASDAQ:TSHA)

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) was the target of unusually large options trading on Thursday. Stock traders acquired 6,277 call options on the stock. This is an increase of 2,571% compared to the average daily volume of 235 call options.

Taysha Gene Therapies Trading Up 8.1%

Shares of TSHA opened at $6.43 on Friday. The business has a 50-day moving average of $4.63 and a 200 day moving average of $4.77. Taysha Gene Therapies has a fifty-two week low of $1.22 and a fifty-two week high of $6.50. The company has a debt-to-equity ratio of 0.20, a quick ratio of 12.23 and a current ratio of 12.23. The firm has a market cap of $1.85 billion, a P/E ratio of -18.91 and a beta of 1.10.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. The business had revenue of $5.49 million for the quarter, compared to analysts’ expectations of $1.89 million. As a group, research analysts forecast that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Transactions at Taysha Gene Therapies

In related news, CEO Sean P. Nolan sold 41,312 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $190,448.32. Following the completion of the transaction, the chief executive officer directly owned 2,908,257 shares in the company, valued at $13,407,064.77. This represents a 1.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $4.46, for a total transaction of $892,000.00. Following the completion of the transaction, the insider directly owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. The trade was a 14.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 598,623 shares of company stock valued at $2,772,188. 3.78% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC increased its holdings in shares of Taysha Gene Therapies by 178.5% in the 1st quarter. SG Americas Securities LLC now owns 2,176,742 shares of the company’s stock worth $9,730,000 after buying an additional 1,395,268 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Taysha Gene Therapies by 698.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,577 shares of the company’s stock worth $141,000 after purchasing an additional 22,373 shares during the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Taysha Gene Therapies in the 4th quarter worth about $920,000. Invesco Ltd. boosted its holdings in shares of Taysha Gene Therapies by 376.3% in the 4th quarter. Invesco Ltd. now owns 1,332,780 shares of the company’s stock worth $7,330,000 after purchasing an additional 1,052,987 shares in the last quarter. Finally, Oracle Investment Management Inc. bought a new position in shares of Taysha Gene Therapies during the 4th quarter valued at about $1,458,000. 77.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on TSHA. Truist Financial upgraded Taysha Gene Therapies to a “strong-buy” rating in a report on Wednesday, March 25th. Raymond James Financial reiterated a “strong-buy” rating and issued a $13.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Canaccord Genuity Group upped their target price on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, April 6th. Wall Street Zen raised shares of Taysha Gene Therapies from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Finally, Wells Fargo & Company boosted their price objective on Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $11.64.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.